An interventional study of Active repetitive transcranial magnetic stimulation and Sham repetitive transcranial magnetic stimulation in Spinocerebellar Ataxia Type 3, sponsored by Ning Wang, MD., PhD.. Completed at 1 site in China. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-16.
Sponsored by Ning Wang, MD., PhD. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Machado-Joseph Disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common spinocerebellar ataxia worldwide.Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy used to treat depression and cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a 15 day treatment with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) can improve symptoms (motor symptoms and non-motor symptoms) in patients with MJD.
Machado-Joseph Disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common spinocerebellar ataxia worldwide. MJD shows remarked clinical heterogeneity and presents with various clinical manifestations, including cerebellar ataxia, limb incoordination, dysarthria, sleep disorders, axonal neuropathy, dystonia, pyramidal signs and, diplopia. No effective treatment is currently available for MJD.
Repetitive transcranial magnetic stimulation (rTMS)enables non-invasive modulation of cortical excitability. rTMS targeting cerebellar structures is capable of inducing long-lasting changes in the excitability of cerebello-thalamocortical pathways.
Subjects will be randomized in two groups, one receiving a consecutive 15-day treatment with 1 Hz of repetitive transcranial magnetic stimulation and the other receiving sham stimulation with identical parameters. Patients will be clinically assessed at baseline, during intervention period at 7 days and 15 days immediate after treatment.
33 studies on the registry are indexed under Machado-Joseph Disease; 5 are open to participants now.
This study's enrollment of 39 is above the median of 23 across 21 interventional studies indexed under Machado-Joseph Disease.
Browse Machado-Joseph Disease studies →Ning Wang, MD., PhD. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1 .Patients with detectable clinical signs and confirmed genetic diagnosis with SCA3.
Exclusion Criteria:
Patients who have concomitant epilepsy. 2. History of seizure or heat convulsion. 3. Patients on neuroleptics. 4. History or current unstable hypertension. 5. History of head injury or neurosurgical interventions. 6. History of any metal in the head (outside the mouth). 7. Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 days with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) with active mood.
Device: Active repetitive transcranial magnetic stimulation
15 days with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) with sham mood.
Device: Sham repetitive transcranial magnetic stimulation
Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation
Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
ICARS
The International Cooperative Ataxia Rating Scale (ICARS)
Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment.
BBS
Berg Balance Scale (BBS)
Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment
SARA
Scale for the Assessment and Rating of Ataxia (SARA)
Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment
Tandem gait
Tandem gait is a gait (method of walking or running) where the toes of the back foot touch the heel of the front foot at each step.
Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment
10 Metre Walk Test
The 10 Metre Walk Test is a performance measure used to assess walking speed in metres per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function.
Time frame: At baseline, during intervention period at 7 days and 15 days immediate after treatment
Static Stability Test
Static Stability Test is a objective test use Pro-kin machine to evaluate patient's standing balance.
Time frame: At baseline and 15 days immediate after treatment
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is the most commonly used instrument to assess the subjective sleep quality of adults in clinical and community settings
Time frame: At baseline and 15 days immediate after treatment
Athens Insomnia Scale (AIS)
The AIS is a self-reported questionnaire designed to measure the severity of insomnia based on the diagnostic criteria of the International Classification of Diseases, 10th revision (ICD-10).
Time frame: At baseline and 15 days immediate after treatment
Mini-Mental State Examination (MMSE)
In addressing cognitive screening tools, the MMSE and the MoCA are the most commonly used methods in cognitive impairment detection in both clinical and research fields.
Time frame: At baseline and 15 days immediate after treatment
Montreal Cognitive Assessment (MoCA)
In addressing cognitive screening tools, the MMSE and the MoCA are the most commonly used methods in cognitive impairment detection in both clinical and research fields.
Time frame: At baseline and 15 days immediate after treatmen
Hamilton Anxiety Scale (HAMA)
HAMA contains 14 questions; each question includes 5 items. Responses are scored as 0 (never), 1 (mild), 2 (moderate), 3 (severe), or 4 (extremely serious). The total score of HAMA is operationally categorized as follows: no anxiety (score 0-6), mild and moderate anxiety (score 7-13), severe anxiety (score ≥ 14).
Time frame: At baseline and 15 days immediate after treatmen
Hamilton Depression Scale (HAMD)
HAMD contains 17 questions; each question includes 5 items. Responses are scored as 0 (never), 1 (mild), 2 (moderate), 3 (severe), or 4 (extremely serious). The total score of HAMD can be classified into normal (score 0-6), mild and moderate (score 7-23), severe depression (score ≥ 24).
Time frame: At baseline and 15 days immediate after treatmen
Ran from Dec 2018 to primary completion in Oct 2019, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ning Wang, MD., PhD.